Value of onconeuronal antibodies in checkpoint...
An increasing number of patients will be exposed to immune checkpoint inhibitors (ICIs) in the forthcoming future; therefore, it is crucial for neurologists to acquire experience in managing neurological immune‐related adverse events (n‐irAEs) associated with their use.
Dubey et al recently described in Annals of Neurology patients with n‐irAEs. Surprisingly, they stated that in both the literature and in their series the neurological presentations rarely mimicked those of classical paraneoplastic neurological syndromes (PNSs). Moreover, they suspected that “these presentations are likely due to autoimmune etiology rather than paraneoplastic response against a shared autoantigen between the tumor and neural tissue.” Vogrig and al. do not agree with these statements and expose their aguments.
